Human Trials

Ablynx’s vobarilizumab fails to meet primary endpoint in phase II lupus study

Ablynx’s lupus erythematosus treatment vobarilizumab has failed to meet primary endpoint in the phase II dose-ranging study.

Mitsubishi Tanabe, Hitachi to use AI for improving efficiency of clinical trials

Mitsubishi Tanabe Pharma has partnered with Hitachi to improve the efficiency of clinical trials for the development of new drugs through the latter's artificial intelligence (AI) technology.

Roche’s lung cancer combination drug shows significant survival benefit

Roche has announced that its Tecentriq (atezolizumab) combined with Avastin (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) showed a clinically significant survival benefit in a phase III lung cancer study.

GSK begins phase III trial of Benlysta, rituximab combo in systemic lupus erythematosus

GSK has commenced a phase III trial to evaluate Benlysta (belimumab) in combination with rituximab in adult patients with systemic lupus erythematosus (SLE).

Arena’s etrasimod meets primary and secondary endpoints in ulcerative colitis trial

Arena Pharmaceuticals has reported positive topline phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC).

Heron’s pain drug succeeds in phase 3 bunionectomy and hernia repair trials

Heron Therapeutics’ pain drug HTX-011 has succeeded in two phase 3 trials in patients undergoing bunionectomy and hernia repair by meeting all their primary and key secondary points.

FDA puts clinical hold on Solid Biosciences’ Duchenne gene therapy trial

The US Food and Drug Administration (FDA) has placed a clinical hold on Solid Biosciences' IGNITE DMD phase Phase I/II trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD).

AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid study

AbbVie, along with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.

Janssen’s Invokana reduces cardiovascular risk in diabetes patients

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced results of a new analysis showing that Invokana (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk.